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ABSTRACT 
Purpose: Impetigo affects approximately 162 mil- 
lion children worldwide at any given time. Lack of 
consensus on the most effective treatment strategy for 
impetigo and increasing antibiotic resistance continue 
to drive research into newer and alternative treatment 
options. We conducted a systematic review to assess the 
effectiveness of new treatments for impetigo in endemic 
and nonendemic settings. 
Methods: We searched PubMed, MEDLINE, 
CINAHL, Web of Science, and Embase via Scopus 
for studies that explored treatments for bullous, 
nonbullous, primary, and secondary impetigo 
published between August 1, 2011, and February 29, 
2020. We also searched online trial registries and hand- 
searched the reference lists of the included studies. We 
used the revised Cochrane risk of bias (version 2.0) tool 
for randomized trials and the National Heart, Lung, 
and Blood Institute for nonrandomized uncontrolled 
studies to assess the risk of bias. 
Findings: We included 10 studies that involved 
6651 participants and reported on 9 treatments in the 
final analysis. Most clinical trials targeted nonbullous 
impetigo or did not specify this. The risk of bias 
varied among the studies. In nonendemic settings, 
ozenoxacin 1% cream appeared to have the strongest 
evidence base compared with retapamulin and a 
new minocycline formulation. In endemic settings, 
oral co-trimoxazole and benzathine benzylpenicillin G 
injection were equally effective in the treatment of 
severe impetigo. Mass drug administration intervention 
emerged as a promising public health strategy to reduce 
the prevalence of impetigo in endemic settings. 
Implications: This review highlights the limited 
research into new drugs used for the treatment of 
impetigo in endemic and nonendemic settings. Limited 
recent evidence supports the use of topical ozenoxacin 
or retapamulin for impetigo treatment in nonendemic 
settings, whereas systemic antibiotics and the mass 
drug administration strategy have evidence for use 
in endemic settings. Given the troubling increase in 
resistance to existing treatments, there is a clear need to 
ensure the judicious use of antibiotics and to develop 
new treatments and alternative strategies; this is 
particularly important in endemic settings. PROSPERO 
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Impetigo is a highly contagious, superficial bacterial
skin infection that most commonly occurs in children
2 to 5 years of age typically because of damage to
the cutaneous barrier.1 , 2 It is classified as a primary
infection with direct bacterial invasion or a secondary
infection (eg, in association with scabies or eczema).3–5 
Impetigo clinically presents as a bullous or nonbullous
type.4 Nonbullous impetigo is the most common
form of impetigo and is caused by Staphylococcus
aureus in 80% of cases and group A β-hemolytic
Streptococcus alone or in combination with S aureus in
the remainder.1 , 4 Bullous impetigo is almost exclusively
caused by S aureus.1 , 6 
An estimate of 162 million children globally
experience impetigo at any given time.7 There is a dis-
proportionately high prevalence reported in Indigenous
Australian children.7 Almost half of the Aboriginal
children (45%) in the northern regions of Australia
have impetigo at any time, equaling approximately
16,000 children.7 An estimated approximately two-
thirds of these children are treated for impetigo before
their first birthday.8 The risk factors for impetigo
include young age, crowding, close contact, and warm
humid conditions.9 When left untreated, impetigo can
lead to severe skin, soft tissue and bone infections,
and sepsis, which contribute to a 5% to 10% case
fatality rate.10 Impetigo also leads to serious sequelae,
including glomerulonephritis and potentially acute
rheumatic fever and rheumatic heart disease.10 
Management strategies of impetigo vary, depending
on whether the condition is localized or widespread
across the body, the resistance patterns to causative
agents, and the guidelines in place. Bullous or
nonbullous impetigo with a limited number of lesions
is typically treated with topical antibiotics, such
as mupirocin or retapamulin.11 When impetigo is
associated with numerous lesions, as in remote com-
munities where impetigo is considered endemic, oral
(such as dicloxacillin, cephalexin, and trimethoprim-2 
Please cite this article as: G. Gahlawat et al., Emerging Treatment Strategie
Review, Clinical Therapeutics, https://doi.org/10.1016/j.clinthera.2021.04sulfamethoxazole) or intramuscular (benzathine peni-
cillin G) antibiotics are recommended.10–12 
The rapid emergence and spread of antibiotic-
resistant bacteria, including methicillin-resistant S au-
reus (MRSA), pose serious threats to public health.13 , 14
The increase in antimicrobial resistance to topical
mupirocin and fusidic acid 1 , 15–18 has had adverse
consequences for individuals and communities, necessi-
tating the development of newer treatment alternatives
or strategies to promote the judicious use of existing
drugs. There are a variety of treatments for impetigo
with varying level of evidence, which range from
topical and oral treatment antibiotics to disinfectants
and herbal therapies.6 , 19 The previous major systematic
review on impetigo treatments was published in 2012
by Koning et al 19 and included studies published until
2011. The review concluded that topical mupirocin
and fusidic acid are equally or more effective than
oral treatment and highlighted the lack of evidence
to support disinfection for impetigo management.19 
Another focused review published in 2019 explored
treatment strategies for commonly encountered infec-
tious skin conditions, including impetigo in endemic
settings, and covered a broad range of interventions,
including complementary or alternative therapies, hand
washing and hygiene practices, and other public health
interventions.20 In recent years, newer treatments have
emerged, and an updated review of existing treatments
and strategies could better inform clinical practice
and future research. Therefore, this systematic review
aims to examine the most recent evidence (since 2011)
related to newer treatment options and strategies
to reduce the burden of impetigo in endemic and
nonendemic settings. 
METHODS 
This systematic review was conducted in accordance
with the Preferred Reporting Items for Systematic
Reviews and Meta-Analysis (PRISMA) guidelines and
was registered in PROSPERO (CRD42020173042). 
Search Strategy 
We searched PubMed, MEDLINE via EBSCOhost,
CINAHL via EBSCOhost, Web of Science, and Embase
via Scopus for studies published between August 1,
2011, and February 29, 2020. The search duration was
restricted to this period because of the review published
in 2012. Keywords used in the search included impetigo
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treatment OR drug therapy OR staphylococc ∗ OR
streptococc ∗ and skin and infection ∗. A detailed search
strategy is available in the Appendix. 
ELIGIBILITY SCREENING AND STUDY 
SELECTION 
This systematic review included randomized controlled
trials (RCTs), prospective studies, and pre-post inter-
ventional studies that assessed the effect of drugs on
bullous or nonbullous impetigo or the prevalence of
impetigo after intervention. Mass drug administration
(MDA) studies that evaluated impetigo as an outcome
were also included. Studies targeting participants of
any age in primary or secondary care settings were
included. Case reports or studies that did not report
the clinical success rate, conference or dissertation
abstracts without full texts, and other in vitro and
in vivo studies were excluded. The articles identified
based on the key word search were exported to
Covidence 21 for study screening. Two reviewers (G.G.
and W.T.) independently screened the articles using
titles, abstracts, and full texts to identify studies
that met the inclusion criteria. Whenever inconsisten-
cies arose between the reviewers, a consensus was
sought through the involvement of a third reviewer
(J.T.). 
Data Extraction and Synthesis 
Study characteristics, such as setting, design, and
participant demographic details, were extracted. Pop-
ulation included authors, journal, study year, location,
setting, study aims, and demographic characteristics.
Intervention included treatment agent, intervention
type, frequency, dose, duration, and any cointervention.
Outcomes included clinical cure (or improvement
of impetigo reported 7–14 days after treatment),
impetigo prevalence before and after MDA, and
secondary outcomes and results (including micro-
biologic responses, adverse effects, and user satis-
faction). Study design included participants (studies
targeting individuals with a diagnosis of bullous
or nonbullous impetigo, identified by a health care
professional), inclusion and exclusion criteria, sample
size, comparison groups, and randomization. The data
extracted were presented using a textual narrative
synthesis in a tabular format ( Table I ). Meta-analysis
was not performed because of the heterogeneity of
studies.  2021 
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The Cochrane risk of bias (version 2.0) assessment
tool 22 was applied for RCTs. Two reviewers indepen-
dently completed the assessment, with disagreements
resolved via discussion. The risk of bias for non-RCTs
was assessed using a tool by the National Heart, Lung,
and Blood Institute.23 
RESULTS 
The search resulted in a total of 4757 titles. After
removal of duplicates and studies not relevant to
our objectives, 47 studies were assessed for eligibility,
and 10 were included in the final data synthesis
( Figure 1 ).12 , 24–32 
Characteristics of the Included Studies 
Overall, 10 studies (7 targeted and 3 com-
munity MDA interventions) were included in this
review 12 , 24–32 ( Table I ). 
Studies in Nonendemic Settings 
The clinical studies comprised 4 RCTs 25 , 26 , 28 , 29 that
evaluated the efficacy and tolerability of ≥1 drugs and
2 non-RCTs.24 , 27 The clinical studies were conducted in
the United States, Israel, and Spain, and 2 studies 26 , 28
targeted a multinational cohort, including the United
States, Russia, South Africa, Germany, Romania, Spain,
and Ukraine. 
Studies in Endemic Settings 
Four studies were conducted in endemic settings. Of
these, 1 clinical study was conducted in Australia,12
and 3 MDA interventions were conducted in Fiji 32
and the Solomon Islands.30 , 31 Since the last systemic
review on impetigo treatments in 2012, the Australian
study 12 is the only non-MDA RCT (open-label, ran-
domized, controlled, noninferiority trial) published in
an endemic setting that compared oral administration
of short-course cotrimoxazole with intramuscular
benzathine benzylpenicillin. The other 3 were MDA
studies, including 2 randomized interventions 30 , 32 and
1 pre-post interventional study.31 The MDA studies,
other than the one by Marks et al,30 were designed
to assess the impact of MDA measures on scabies as
the primary outcome, and impetigo was only examined
as a secondary outcome; none assessed impetigo
alone. 
A clinical diagnosis of impetigo was made in all the
studies included in this systematic review. Laboratory3 


































Table I. Characteristics of included studies. 
Study Study Setting 
and Country 
of Study 
No. of Pa- 
tients/Mean 
(SD) Age, y 




















Studies from nonendemic settings 
Bohaty 
et al, 22 2014 
Outpatient 
dermatology 










9 months to 
















aureus : 26 (72.2%); 
• MRSA: 7 (19.4%); 
MSSA: 19 (52.8%); 
• Streptococcus 
pyogenes; 2 (5.5%); 




















































2 of 7 had 
clinical 
improvement 




























of 66%, 97%, 
and 69%, 
respectively 





Not reported Not reported • Wide range of age 
and ethnicities 
included in the study; 
safety profile appears 
favorable given the 
low number of 
adverse events; small 
































































































Table I. ( continued ) 
Study Study Setting 
and Country 
of Study 
No. of Pa- 
tients/Mean 
(SD) Age, y 

















































• S. aureus : 21 
(65.6%); S pyogenes : 
13 (40.6%); MRSA: 
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respective 
patients at 
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occurred in 6 
patients 
treated: 2 in 
the 1% group 
and 4 in the 
4% group 








rate of 85.5% 
for 1% 
minocycline 




randomized nature of 
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the study; small 
sample 




















































































Table I. ( continued ) 
Study Study Setting 
and Country 
of Study 
No. of Pa- 
tients/Mean 
(SD) Age, y 
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(79.3%); S aureus : 
285 (61.4%); S 
pyogenes: 214 
(46.1%) 
Twice daily 1% 
ozenoxacin 
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P = 0.003). 


































gitis (n = 4 in 
ozenoxacin 









site pain and 
irritation 
(n = 2 in 
retapamulin 
group) 
Not reported Treatment 
adherence 
was 99.6% in 
ozenoxacin 




• Strengths: strong 
randomization 
process performed by 
an independent 
































































































Table I. ( continued ) 
Study Study Setting 
and Country 
of Study 
No. of Pa- 
tients/Mean 
(SD) Age, y 





















et al, 26 
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SIRS score of 
at least 8; a 
total 
affected area 
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cm from the 




• Bullous Impetigo –
2 (4.30%) 
• Non-Bullous 
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final single 
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• 25 Mild 
(n = 22) or 
moderate 
(n = 3) 
adverse events 
were reported 
in 21 of 46 
patients 




























































































Table I. ( continued ) 
Study Study Setting 
and Country 
of Study 
No. of Pa- 
tients/Mean 
(SD) Age, y 

















































from 2 to 
100 cm 2 , 
and for 
patients > 12 
years of age, 
the total area 
could not 





• S. Aureus – 223 
(54.3%) 
• S. Pyogenes- 39 
(9.46%) 
• Other Pathogens –
147 (35.9%) 
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[37.9%]; 








after 2 days 
of therapy 
(109 of 125 
[87.2%] vs 
76 of 119 
[63.9%]; 
P = .002) 
• Adverse 
events in 15 
of 411 
patients: 8 in 
the 
ozenoxacin 
group and 7 












Nor reported • Strength: central 
randomization via an 
interactive web 
response system was 
used to allocate 
patients to treatment 
groups, stratified by 
age subset, to ensure 
a 1:1 distribution and 
avoid selection bias; 
limitations: small 
number of children 
with bullous impetigo 
included; data in 
children < 6 mo of 
age are also limited 



























































































Table I. ( continued ) 
Study Study Setting 
and Country 
of Study 
No. of Pa- 
tients/Mean 
(SD) Age, y 
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• Bullous Impetigo –
51 (12.4%) 
• Non-Bullous 
Impetigo – 74 
(18%) 
• S. Aureus – 216 
patients. 




Species – 8 (2.7%) 
• Other Gram 
-Positive Pathogens 
– 3 (1%) 
• Other 
Gram-negative 





daily, at 10- to 
12-h intervals, 
for 5 days. 
OR 
linezolid dosed 
2 or 3 times 
daily, 
depending on 
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performed via 
automated telephone 
system; block size 
remained 
confidential; study 
was blinded until 
after all patients had 
received a clinical 








durations (5 vs 10 
days), which may 
have biased the study 
in favor of linezolid 
treatment; the 
definition of clinical 
success may not 
represent clinical 
practice, and the 
study was not 
powered to show 
statistical outcomes 
between treatment 
groups; 15.4% and 
14.6% of patients in 
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Table I. ( continued ) 
Study Study Setting 
and Country 
of Study 
No. of Pa- 
tients/Mean 
(SD) Age, y 




















Studies from endemic settings (including MDAs) 
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complications 



























































































Table I. ( continued ) 
Study Study Setting 
and Country 
of Study 
No. of Pa- 
tients/Mean 
(SD) Age, y 
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3 time points 
• Not 
reported 
Not reporter Not reported • Limitations: sample 
size too small to draw 
firm conclusions; 
swabs were not taken 
from every individual 
or from every lesion 
on an individual; 
study was not 
blinded; diagnosis of 
impetigo was made 
on clinical grounds 
alone by a single 
experienced physician 




















































































Table I. ( continued ) 
Study Study Setting 
and Country 
of Study 
No. of Pa- 
tients/Mean 
(SD) Age, y 















































• Not reported Single dose of 
20 mg/kg of 
azithromycin 
MDA with 2 
doses of oral 
ivermectin, 200 
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Not reported Not reported • Strength: to allow 
for estimates of 
prevalence to be 
generalized across 
population; 10 
different villages were 
assessed at 12 mo 
after MDA; 
limitations: given this 
is a nonrandomized 
pragmatic 
before-and-after 
design in a large-scale 
setting, it is difficult 
to rule out the 
contribution of other 
factors 



























































































Table I. ( continued ) 
Study Study Setting 
and Country 
of Study 
No. of Pa- 
tients/Mean 
(SD) Age, y 
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of permethrin 
cream followed 
by a second 
dose 7–14 days 
apart if scabies 
observed at 
baseline OR 
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testing, such as a bacterial culture, was included
in 6 studies to determine the causative agent of
impetigo.24–26 , 28–30 
Efficacy and Tolerability of Interventions 
Studies from Nonendemic Settings 
Topical Ozenoxacin. Three clinical studies evalu-
ated the efficacy and tolerability of 1% topical
ozenoxacin.26–28 Of these, 2 RCTs 26 , 28 that involved
723 participants provided suitable data for pooled
analysis, revealing superior efficacy of ozenoxacin over
placebo (relative risk = 1.52; 95% CI, 1.25–1.85) when
applied twice daily for 5 days. 
The first study by Gropper et al 26 recruited 464
individuals predominantly with nonbullous impetigo
(79%) from 27 outpatient clinics in 5 countries.
Ozenoxacin was superior to placebo in terms of14 
Please cite this article as: G. Gahlawat et al., Emerging Treatment Strategie
Review, Clinical Therapeutics, https://doi.org/10.1016/j.clinthera.2021.04clinical efficacy (defined based on changes in skin
infection rating scale [SIRS] scores at day 6–7) after
5 days of application (35% vs 19.2%; P = 0.003).
The active control (topical retapamulin) in this study
had slightly greater clinical efficacy than ozenoxacin
(38%). The microbiological success (ie, absence of the
pathogen after 6–7 days) was 79% in the ozenoxacin
group compared with 57% for placebo ( P < 0.0001).
Retapamulin, despite being effective in microbiological
clearance, was significantly slower in terms of this effect
than ozenoxacin (60% vs 75% for retapamulin vs.
ozenoxacin after 3–4 days; P = 0.0087). Treatment
adherence was high in all groups. A total of 35 patients
reported adverse effects, such as nasopharyngitis,
rhinitis, and application site pain and irritation, with
most of the adverse effects reported by those treated
with retapamulin. Volume xxx Number xxx 
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The second study involving ozenoxacin (n = 412)
targeted patients with S aureus infection (54%) and
was also a multinational study conducted across 6
countries.28 After 5 days of twice-daily treatment, there
was a higher clinical success (cure of impetigo) among
those treated with ozenoxacin compared with placebo
(54% vs 38%; P = 0.001). Minor adverse events
were reported in 4% of people taking ozenoxacin as
opposed to 3% in the placebo group, including rosacea
and seborrheic dermatitis in the ozenoxacin group and
dermatitis and skin tightness in the placebo group. 
The third study on ozenoxacin was a Phase I
open-label trial that primarily aimed to establish the
bioavailability and tolerability of the drug in 46
individuals.27 Overall, 94% of the individuals had
nonbullous impetigo and were treated with a single
0.5-g dose of 1% ozenoxacin cream on the first day,
twice-daily application for 4 days, and a single dose on
day 6. On follow-up, nearly half (49%) of participants
were clinically cured from impetigo (based on a
reduction in the SIRS score from baseline), with 51%
of the individuals demonstrating clinical improvement.
Overall, 22 mild adverse events were reported in 46%
of participants, and there were 3 moderate adverse
events: anemia, tympanic membrane perforation, and
superficial thrombophlebitis. 
Retapamulin. The first study on retapamulin was a
double-blind, comparative RCT that compared 1%
retapamulin applied twice daily for 5 days with oral
linezolid (10 mg/kg for children aged < 5 years and
600 mg/kg for those aged > 12 years) dosed 2 to 3
times daily for 10 days.29 It included 410 patients with
impetigo as well as patients with secondarily infected
wounds and lacerations. Clinical success (defined as
cure from impetigo caused by MRSA [ie, based on
microbiological testing] or clinical improvement) was
significantly higher in the linezolid group (84.2% vs
57%), with a −27% difference in success rate (95%
CI, −46.0% to −8.7%). Frequency of adverse events
were comparable for the 2 groups (31% and 27%,
respectively). Treatment acceptability was higher for
retapamulin, with 64% reporting a preference of the
topical application over oral linezolid. 
The second retapamulin study was a prospective,
single-center non-RCT of 35 patients that evaluated
the efficacy of retapamulin 24 for treatment of impetigo,
including impetigo caused by MRSA (n = 7). After
treatment with retapamulin twice daily for 5 days, 2021 
Please cite this article as: G. Gahlawat et al., Emerging Treatment Strategie
Review, Clinical Therapeutics, https://doi.org/10.1016/j.clinthera.2021.045 of 7 patients had clinical success, whereas 2 of 7
had clinical improvement at day 7. The wound size of
impetigo lesions had also decreased significantly by a
mean of 71% at follow-up. Retapamulin was found
to have a favorable safety profile, with only 11% of
the patients having mild-to-moderate adverse events,
such as burning sensation at the application site, cough,
furuncle, or upper respiratory tract infection, with no
serious adverse effects reported. 
Minocycline. A study conducted in outpatient clinics
in Israel compared the efficacy of 1% minocycline foam
twice daily for 7 days with the 4% minocycline foam
formulation.25 In this RCT, the main causative agent
for impetigo was also S aureus, with 75% of patients
diagnosed with nonbullous impetigo. Clinical cure was
achieved in 57% and 50% of people treated with the
1% and 4% minocycline formulations, respectively.
The minocycline foam was rated to have moderate-to-
excellent satisfaction and usability in 90% of the study
participants. The relatively high treatment adherence
further emphasized this, with 86% and 75% of
participants reporting adherence to the 1% and 4%
treatments, respectively. 
Studies From Endemic Settings 
The first study was an open-label RCT 12 that
compared the efficacy of 2 different doses and
durations of oral cotrimoxazole (4 mg/kg plus 20
mg/kg per dose given twice daily for 3 days and 8
mg/kg plus 40 mg/kg per dose given for 5 days) with
benzathine benzylpenicillin injection. The study was
conducted among 508 Indigenous Australian children
with severe impetigo and a mean (SD) age of 7 (4.6-
9.7) years. Treatment success (defined as healing or
improvement of sores based on digital imaging) was
85% for all 3 treatment regimens on day 7. The
absolute difference between the benzylpenicillin and
the pooled cotrimoxazole group combining both the
3- and 5-day regimens was 0.5% (95% CI, −6.2%
to 7.3%), indicating noninferiority of cotrimoxazole.
However, a significant difference was found in the
number of adverse events reported: –31% in the
benzathine benzylpenicillin (mostly injection site pain)
and 2% in the combined cotrimoxazole groups. High
treatment adherence ( > 95%) was reported with oral
cotrimoxazole. No differences were found in outcomes
between the 3- and 5-day cotrimoxazole regimens. 15 
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Figure 2. Methodological quality summary. 
Figure 3. Methodological quality graph, as per- 





The other studies in endemic settings were MDA
interventions in remote community settings.30–32 The
study by Marks et al 30 conducted in Solomon Islands
compared single-dose ivermectin (200 g/kg) with a
combination of single-dose ivermectin (200 g/kg) and
azithromycin (30 mg/kg) in reducing impetigo. The
baseline impetigo prevalence was 10.1% and 12.1%
in the ivermectin-only and combination treatment
groups, respectively. There was no difference in
outcome; after 12 months, there was a 75% and 73%
relative reduction in impetigo prevalence from baseline,
respectively. Another MDA study conducted in the
Solomon Islands was a pre-post intervention study
that evaluated the tolerability and feasibility of large-
scale administration of azithromycin and ivermectin in
reducing impetigo prevalence.31 The whole province
was given single-dose azithromycin (20 mg/kg) and
2 doses of ivermectin (200 g/kg) administered 7
to 14 days apart. The study concluded that the
coadministration of these drugs led to a 16% absolute
reduction in impetigo prevalence and a 74% relative
reduction from baseline (24.8%) to 12 months (6.4%)
after treatment. There was also a significant reduction
in the outpatient clinic presentations for skin sores,
abscesses, and boils, when the period 3 months before
the MDA was compared with the period 3 months after
(51%; 95% CI, 49%-53%). 
The third MDA study was conducted in Fiji to
compare the impact of an ivermectin-based MDA
(given at 200 g/kg) with a guideline-recommended dose
of permethrin and a standard care group (involved
1 dose of permethrin to affected people and their
contacts with a second dose after 14 days if symptoms
persisted).32 This trial found that the prevalence of
impetigo decreased in all 3 treatment groups, with the
highest relative reduction observed in the ivermectin
group (67%; 95% CI, 52%-83%). Adverse events
were more common in the ivermectin than permethrin
group (16% vs 7%) and included itchy skin, headache,
abdominal pain, joint pain, and dizziness. 
Risk of Bias Assessment 
The risk of bias varied among the studies and across
different domains ( Figures 2 and 3 ). Two clinical trials
targeting ozenoxacin 1% cream,26 , 28 a trial involving
retapamulin,29 and an ivermectin-based MDA trial 32 
had a low risk of bias in the overall assessment as well
as in individual domains. The lack of description of
the participation rate and an inadequate sample size16 
Please cite this article as: G. Gahlawat et al., Emerging Treatment Strategie
Review, Clinical Therapeutics, https://doi.org/10.1016/j.clinthera.2021.04and/or power description were among the deficiencies
identified from the nonrandomized studies.24 , 27 Finally,
the RCTs on ozenoxacin were industry funded, and
the investigators declared affiliations as employees or
consultants of the sponsor company. Volume xxx Number xxx 
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This study presents an updated review of treatment
strategies for impetigo in endemic and nonendemic
settings. Although the number of publications on
impetigo treatments from the past 10 years is
limited, a few treatment alternatives have emerged. In
nonendemic settings, topical drugs, such as ozenoxacin,
retapamulin, and a new minocycline formulation, have
been investigated through RCTs and other clinical
studies. Of these, ozenoxacin 1% cream has the
strongest evidence base to date, as demonstrated by
2 multinational trials.26 , 28 This new nonfluorinated
quinolone antibiotic has superior efficacy without
significant tolerability concerns when compared with
placebo. It possesses potent bacteriostatic and bacteri-
cidal properties against gram-positive pathogens such
as S. aureus and Streptococcus pyogenes,33 , 34 although
the reported clinical success rates are lower than those
for retapamulin or sodium fusidate.29 , 35 , 36 This finding
could be related to the more stringent criteria used to
define clinical success in the ozenoxacin studies.26 , 28 
Nevertheless, in light of this evidence, the US Food and
Drug Administration approved ozenoxacin for use in
2017 for treatment of impetigo in adults and children
aged ≥2 months.37 
Another topical agent investigated in nonendemic
clinical settings during the past 10 years is retapamulin,
a new topical antibiotic from the pleuromutilin class.38
It may have similar efficacy with ozenoxacin.26 , 28 
Retapamulin was approved for use in 2007 for
the treatment of impetigo in adults and children
from the age of ≥9 months by the US Food and
Drug Administration.39 One RCT 29 comparing 1%
retapamulin ointment with oral linezolid found that
the clinical success observed with retapamulin was
similar to that reported in previous studies 35 , 36 but
that linezolid was superior. A non-RCT clinical study
also demonstrated high clinical efficacy of the 1%
retapamulin ointment in patients with MRSA.24 In
addition, its tolerability profile has been established
in a postmarketing surveillance study.40 Overall,
the evidence supports the use of the drug for the
management of impetigo and other uncomplicated
bacterial skin infections.41 , 42 
Although the burden of impetigo is enormous in
endemic settings, the only clinical trial that explored
the treatment of impetigo in endemic areas was
conducted in 2009 to 2012, targeting Australian
Aboriginal children with nonbullous impetigo living 2021 
Please cite this article as: G. Gahlawat et al., Emerging Treatment Strategie
Review, Clinical Therapeutics, https://doi.org/10.1016/j.clinthera.2021.04in the Northern Territory.12 The results indicated
that oral cotrimoxazole (for 3 or 5 days) was not
inferior to benzathine benzylpenicillin injection in
treating severe impetigo. Benzathine benzylpenicillin is
not recommended in most endemic and nonendemic
settings where MRSA is uncommon as first-line
treatment of impetigo; rather oral cloxacillin (or equiv-
alent) or cephalexin is the usual recommendation.11 
Nonetheless, this was an important finding in the
Australian context given oral treatments have better
uptake than injectable forms of treatments. The limited
treatment options in this setting indicate the need
to ensure the judicial use of existing antibiotics and
to find sustainable alternative treatment strategies to
tackle the enormous burden of skin infections in these
settings. 
We evaluated community-based MDA as a strategy
to reduce the prevalence of impetigo in endemic set-
tings. We found 3 ivermectin-based MDA interventions
that targeted scabies and had an associated benefit in
reducing the occurrence of impetigo,30–32 suggesting
that managing causes that underlie impetigo, such
as scabies, may be effective in preventing impetigo
in such settings. The addition of azithromycin to an
ivermectin-based MDA had no apparent benefit in
further reducing impetigo, emphasizing the fact that
the reduction in impetigo was largely related to the
decrease in scabies.30 On the contrary, there was an
increase in macrolide-resistant S aureus strains after
adding azithromycin to the MDA. This increase is
important in view of induction in resistant strains
after azithromycin was administered as a regimen for
trachoma MDA 43 and highlights the need to carefully
assess the use of antibiotics in such programs. 
On the basis of the Australian New Zealand
Clinical Trials Registry, only 2 registered trials are
currently examining the effect of topical antibiotics
and antiseptics for the treatment of impetigo. One is a
pilot RCT comparing topical hydrogen peroxide or soft
white paraffin ointment with mupirocin ointment in
the Australian general practice setting (awaiting ethics
approval, ACTRN12619001366145p), and the other
is an RCT in New Zealand assessing the efficacy of
topical fusidic acid and hydrogen peroxide for mild
impetigo in school children (ACTRN1261000356460),
which is close to completion. Given the size of the
burden of impetigo, we believe there is a need for more
trials, especially in endemic settings. 17 
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Implications for Practice 
Considering the significant burden of skin infections,
such as impetigo, and the increase in antibiotic
resistance, treatment choices are limited, especially in
people with impetigo caused by MRSA. Ozenoxacin
is highly effective against methicillin-susceptible S
aureus , MRSA, and S pyogenes.44 Furthermore, it
has a superior resistance profile when compared
with quinolone antibiotics because of its ability to
simultaneously inhibit bacterial DNA gyrase and
intravenous topoisomerase, whereas most quinolones
bind with only 1 of the 2.45 It is also relatively less
affected by the efflux pumps that some bacteria use
for resistance.45 Overall, ozenoxacin appears to be
a promising treatment alternative, although further
clinical studies are needed to establish its efficacy
and safety across different settings. Retapamulin is
recommended by the Infectious Diseases Society of
America for treatment of bullous and nonbullous
impetigo 11 ; however, the emergence of resistant
bacterial strains (eg, S aureus ) 41 , 46 , 47 raises potential
concerns for long-term clinical usefulness, particularly
for impetigo caused by MRSA. The cost associated 6 , 48
with newly introduced treatments, such as ozenoxacin
and retapamulin, as opposed to off-patent products,
such as mupirocin and fusidic acid, is too high to
be afforded by the most vulnerable communities in
resource-limited settings. Their use has been therefore
limited to settings such as North America and Europe.
In addition to oral cotrimoxazole or benzathine
penicillin G injection, MDA has emerged as an
effective treatment strategy for community-based
impetigo management campaigns in endemic settings.
Ivermectin-based MDA, targeting scabies, had a
positive spillover effect on impetigo. In addition, recent
works further found the benefit of MDA in reducing
the prevalence of impetigo even at 24 49 and 36
months 50 after the intervention, highlighting the long-
term relevance of MDA interventions. Nevertheless,
additional works are warranted to understand the
sustainability of periodic administration, potential
antibiotic resistance, and applicability in other endemic
contexts outside the Pacific. Finally, the National
Institute for Health and Care Excellence (United King-
dom) recommends the use of topical antiseptic (1%
hydrogen peroxide) as a first-line option, especially
for localized, nonbullous impetigo,51 although this
recommendation is based on low-quality evidence that
indicated no significant difference between fusidic acid
and hydrogen peroxide.19 , 51 A Phase IV trial of the18 
Please cite this article as: G. Gahlawat et al., Emerging Treatment Strategie
Review, Clinical Therapeutics, https://doi.org/10.1016/j.clinthera.2021.04efficacy of topical hydrogen peroxide cream for mild
impetigo in school children is currently under way in
New Zealand, and the results of this trial are likely to
provide additional insight into using topical antiseptics
for impetigo treatment.52 The National Healthy Skin
Guidelines (Australia) also recommend washing hands
with soap for the prevention of impetigo in resource-
limited settings,53 although this too was based on
evidence from 1 RCT published in 2005.54 
Limitations 
The inclusion of a small number of studies
with significant heterogeneity precluded a quantitative
analysis of the studies. Because of the limited pool
of high-quality studies, it was not possible to make
treatment recommendations toward clinical guidelines
using the GRADE (Grading of Recommendations,
Assessment, Development, and Evaluations) approach.
The limited pool of studies is mainly attributed to the
lack of development of new drugs for impetigo. Some
of the included studies also had small sample sizes. 
CONCLUSION 
This review identifies a limited evidence base support-
ing the use of topical ozenoxacin or retapamulin for
impetigo treatment in nonendemic settings, whereas
systemic antibiotics and the MDA strategy have
evidence for use in endemic settings. The rapid
emergence of resistant bacteria across the world is
endangering the clinical efficacy of antibiotics and
highlights the need for judicious use of existing
antimicrobials and the development of newer agents.
Although the emergence of drugs such as ozenoxacin
for impetigo treatment in nonendemic settings is a
positive development, the findings are indicative of
the clear need for research into finding tolerable
and effective alternative treatments. Although further
validation is needed, MDA trials targeting scabies
maybe useful in reducing impetigo burden in endemic
settings during a longer period. Substantial morbidity
from impetigo and the resultant sequelae in endemic
settings highlight the clear need for less expensive,
widely available, and acceptable alternative agents and
treatment strategies. In sum, our review calls for well-
designed RCTs, including MDA interventions, for the
treatment of impetigo in endemic settings. 
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